NewAmsterdam Pharma announces 2024 strategic priorities; Phase 3 readouts in 3Q/4Q 2024

NewAmsterdam Pharma Co N.V.

Expects topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024.
Expects topline data from Phase 3 BROADWAY trial in ASCVD in 4Q 2024.
Plans to initiate TANDEM Phase 3 FDC trial in 1Q 2024; topline data in 1Q 2025.
Completes enrollment in PREVAIL CVOT in 1Q 2024; topline data in 2026.
Cash sufficient to fund operations through 2026, beyond three Phase 3 readouts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.